Previous 10 | Next 10 |
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has b...
2023-08-15 08:34:15 ET More on Amicus Therapeutics Amicus Therapeutics Inc. ( FOLD ) Q2 2023 Earnings Call Transcript Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook ...
Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation ...
2023-08-08 15:29:06 ET Amicus Therapeutics Inc. (FOLD) Q2 2023 Results Conference Call August 08, 2023 08:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Daphne Quimi - Chief...
2023-08-08 07:10:05 ET Amicus Therapeutics press release ( NASDAQ: FOLD ): Q2 GAAP EPS of -$0.15 misses by $0.04 . Revenue of $94.5M (+17.1% Y/Y) beats by $4.63M . Cash, cash equivalents, and marketable securities totaled $265.6 million at June 30, 2023, compar...
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold ® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti ® + Opfolda ® Underway; U.S. and U.K. Approvals Expected...
2023-08-07 13:36:26 ET Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $89.87M (+11.4% Y/Y). Over the last 1 year, F...
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2023. Partici...
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Opfolda ...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....